Bliss GVS Pharma Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook
- October 9, 2026
- Posted by: Chaitanya Auti
- Category: Market
CMP Rs 657.00 (9 Oct 2026). 52W range Rs 118.00 to Rs 739.90. PE 50.36. 2027 base Rs 788, bull Rs 821.
Quick Answer
Bliss GVS Pharma share price prediction 2027 centres on a conservative case of Rs 756, a base case of Rs 788 and a bull case of Rs 821, against a current price of Rs 657.00. These targets scale today’s price by reported EPS growth at a constant PE multiple, so they rest on earnings the company has already delivered, not on broker forecasts. The base case implies 19.9% upside from today’s price. The daily technical setup reads mildly bullish.
The Bliss GVS Pharma share price forecast comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 657.00 on NSE as of 9 October 2026, 11.2% below its 52-week high of Rs 739.90, after the company reported net profit of Rs 134.73 crore for FY26.
This Bliss GVS Pharma stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.
Click Here – Get Free Investment Predictions
Bliss GVS Pharma Share Price Today and Key Data
The Bliss GVS Pharma share price today is Rs 657.00 on NSE, down 1.60% on the day. The market capitalisation stands at Rs 7,138 crore. Over the past year the price has risen 316.9% from Rs 157.59. Every Bliss GVS Pharma stock forecast figure below starts from this price.
| Metric | Value |
|---|---|
| Company | Bliss GVS Pharma (BLISSGVS) |
| Current Price | Rs 657.00 |
| 52-Week High | Rs 739.90 (28 September 2026) |
| 52-Week Low | Rs 118.00 (10 November 2025) |
| Market Cap | Rs 7,138 crore |
| PE Ratio | 50.36 |
| Industry PE | 37.59 |
| PB Ratio | 5.98 |
| EPS (TTM) | Rs 13.33 |
| Return on Equity | 10.82% |
| Debt to Equity | 0.02 |
| Dividend Yield | 0.15% |
| Book Value per Share | Rs 112.19 |
What Is the Bliss GVS Pharma Share Price Prediction for 2027?
The Bliss GVS Pharma share price prediction for 2027 is a conservative case of Rs 756, a base case of Rs 788 and a bull case of Rs 821. Against Rs 657.00, these imply 15.1% upside, 19.9% upside and 25.0% upside. They are model scenarios built from reported EPS growth, not broker targets.
| Scenario | EPS Growth Basis | EPS Estimate | PE Multiple | Implied Value | Upside vs Current Price |
|---|---|---|---|---|---|
| Conservative Case | Lower of FY26 growth (50.9%) and 4-year CAGR (70.2%) (capped at 15%) | Rs 15.33 (+15.0%) | Unchanged from today (price to EPS ratio kept constant) | Rs 756 | +15.1% |
| Base Case | Average of the two (capped at 20%) | Rs 16.00 (+20.0%) | Unchanged from today (price to EPS ratio kept constant) | Rs 788 | +19.9% |
| Bull Case | Higher of the two (capped at 25%) | Rs 16.66 (+25.0%) | Unchanged from today (price to EPS ratio kept constant) | Rs 821 | +25.0% |
Each target takes today’s price of Rs 657.00 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. Together they form the Bliss GVS Pharma target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.
Bliss GVS Pharma Share Price Forecast: What Has to Go Right by 2027
Each Bliss GVS Pharma target price below depends on a specific EPS outcome, and the text states that outcome next to the number.
Conservative Case for the Bliss GVS Pharma Share Price Target: Rs 756
Reaching Rs 756 needs EPS to rise 15.0% to Rs 15.33 while the stock keeps its current PE multiple. That follows the slower 4-year EPS CAGR of 70.2%.
Base Case for the Bliss GVS Pharma Share Price Target: Rs 788
Reaching Rs 788 needs EPS to rise 20.0% to Rs 16.00, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 15.8% in Q1 FY27 is below that pace, so earnings need to speed up to reach this level.
Bull Case for the Bliss GVS Pharma Share Price Target: Rs 821
Reaching Rs 821 needs EPS to rise 25.0% to Rs 16.66 with the PE multiple held at today’s level. That is above the 52-week high of Rs 739.90, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 739.90 (52-week high) would be the first technical confirmation.
Bliss GVS Pharma Financial Performance: Revenue, Profit and Margins
Bliss GVS Pharma earned net profit of Rs 134.73 crore on revenue of Rs 1,000.64 crore in FY26, with profit up 49.3% and revenue up 18.2% compared with FY25. Diluted EPS was Rs 12.00 against Rs 7.95 a year earlier, and that earnings base anchors the Bliss GVS Pharma share price forecast.
| Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Operating Margin | Net Margin |
|---|---|---|---|---|---|
| FY22 | 778.95 | 23.13 | 1.43 | 20.04% | 2.97% |
| FY23 | 769.37 | 76.73 | 6.72 | 17.98% | 9.97% |
| FY24 | 798.98 | 81.58 | 7.11 | 23.25% | 10.21% |
| FY25 | 846.22 | 90.26 | 7.95 | 20.15% | 10.67% |
| FY26 | 1,000.64 | 134.73 | 12.00 | 25.36% | 13.46% |
In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 295.18 crore against Rs 242.92 crore a year earlier (+21.5%), and the bottom line was a net profit of Rs 51.37 crore against a net profit of Rs 44.36 crore (+15.8%). Operating margin was 30.11% versus 37.01% in the year-ago quarter. Cash flow from operations was Rs 138.72 crore in FY26 against Rs 105.91 crore in FY25. Together these figures set the earnings base for the Bliss GVS Pharma share price prediction.
Check the Univest Screener for live Bliss GVS Pharma fundamentals
Is Bliss GVS Pharma Overvalued or Undervalued Right Now?
Bliss GVS Pharma trades at a PE of 50.36 against an industry PE of 37.59, which places the stock at a 34.0% premium to the industry average. The price-to-book ratio is 5.98 on a book value of Rs 112.19 per share. Return on equity of 10.82% means the company earns Rs 10.82 of profit for every Rs 100 of shareholder equity.
Debt to equity is 0.02, so borrowings equal about 2% of shareholder equity. The company declared a dividend of Rs 0.50 per share for FY26, a yield of 0.15% at the current price. This valuation context frames the Bliss GVS Pharma stock price prediction for 2027 without relying on any outside forecast.
Bliss GVS Pharma Stock Analysis: Technical Outlook
Bliss GVS Pharma stock trades above its 50-day SMA of Rs 611.60 and above its 200-day EMA of Rs 428.20, and the combined daily indicators read mildly bullish. The 52-week high of Rs 739.90 was set on 28 September 2026, while the 52-week low of Rs 118.00 came on 10 November 2025.
| Indicator | Reading | Signal |
|---|---|---|
| RSI (14) | 44.71 | Weak momentum |
| MACD (12,26,9) | 13.62 vs signal 23.90 | Bearish |
| ADX (14) | 18.13 | Weak trend |
| Supertrend (10,3) | Price above Rs 616.12 | Bullish |
| 50-day SMA | Rs 611.60 | Price above |
| 200-day EMA | Rs 428.20 | Price above |
The nearest support level sits at Rs 616.12 (Supertrend) and Rs 611.60 (50-day SMA). The nearest resistance level sits at Rs 739.90 (52-week high). A sustained move above the nearest resistance would support the Bliss GVS Pharma share price prediction 2027 base case, and this Bliss GVS Pharma stock analysis uses daily candles only. Chart signals add context to the Bliss GVS Pharma share price target without changing the earnings maths.
Bliss GVS Pharma Shareholding Pattern
Promoters hold 35.01% of Bliss GVS Pharma as of Jun 2026, down from 35.44% in Jun 2025 across the last 5 quarters. FII holding is 8.07% (down from 12.65% in Jun 2025) and DII holding is 9.47% (up from 6.54% in Jun 2025), which puts combined institutional holding at 17.54%. Public shareholders own 47.45%. Shareholding data is one input for any Bliss GVS Pharma stock forecast. Ownership is a useful cross-check on any Bliss GVS Pharma share price prediction.
Key Risks to the Bliss GVS Pharma Share Price Target for 2027
Earnings and Margin Risk
Operating margin has ranged from 17.98% to 25.36% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Bliss GVS Pharma stock forecast. Revenue was up 18.2% in FY26, and slower revenue growth would weigh on the profit path.
Valuation Risk
The PE of 50.36 is 34.0% above the industry PE of 37.59. Every target here holds the multiple constant, so a narrowing of that premium would leave returns below these targets even if earnings grow as assumed.
Size and Liquidity Risk
Market capitalisation stands at Rs 7,138 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Bliss GVS Pharma stock price target.
Balance Sheet Risk
Debt to equity of 0.02 means borrowings stand at about 2% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Bliss GVS Pharma share price forecast.
Conclusion
This Bliss GVS Pharma stock analysis puts the share price target range for 2027 at Rs 756 to Rs 821, with a base case of Rs 788 against Rs 657.00 today. The inputs are a PE of 50.36 that sits at a 34.0% premium to the industry average, EPS growth of 50.9% in FY26 and a daily technical setup that reads mildly bullish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.
Download the Univest iOS App or Univest Android App to track Bliss GVS Pharma live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Bliss GVS Pharma Share Price Prediction 2027
What is the Bliss GVS Pharma share price target for 2027?
Ans. The Bliss GVS Pharma share price forecast for 2027 has a conservative case of Rs 756, a base case of Rs 788 and a bull case of Rs 821. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.
What is the Bliss GVS Pharma share price today?
Ans. Bliss GVS Pharma trades at Rs 657.00 on NSE as of 9 October 2026, down 1.60% on the day. The 52-week range is Rs 118.00 to Rs 739.90.
Is Bliss GVS Pharma a good stock to buy for 2027?
Ans. The data points in different directions: the PE of 50.36 is at a 34.0% premium to the industry average, EPS grew 50.9% in FY26 and the daily technical setup reads mildly bullish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.
Can Bliss GVS Pharma stock reach Rs 821 in 2027?
Ans. Reaching Rs 821 needs EPS to rise 25.0% from Rs 13.33 with the PE multiple held at today’s level, plus a daily close above Rs 739.90 (52-week high). This is a scenario, not a guarantee.
What are the support and resistance levels for Bliss GVS Pharma?
Ans. The nearest support levels are Rs 616.12 (Supertrend) and Rs 611.60 (50-day SMA), and the nearest resistance levels are Rs 739.90 (52-week high).
What are the main risks for Bliss GVS Pharma stock in 2027?
Ans. The main risks to the Bliss GVS Pharma share price forecast are a fall in operating margin from the 17.98% to 25.36% range seen since FY22, slower revenue growth after FY26 revenue was up 18.2%, and thin trading volumes. Debt to equity of 0.02 adds balance sheet sensitivity.
How is the Bliss GVS Pharma target price for 2027 calculated?
Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 15.0% growth, the base case 20.0% and the bull case 25.0%, all drawn from the company’s reported FY26 and 4-year EPS growth.